Previous 10 | Next 10 |
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056, Immunosynthen HER2 ADC, restarting; plan...
2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares ( HBANL ) +3% . Genmab ( GMAB ) +3% . Losers: Fluence En...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
2023-11-07 13:34:12 ET Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Conference Call November 07, 2023, 08:00 ET Company Participants Jason Fredette - SVP, IR & Corporate Communications Martin Huber - President, CEO & Director Brian DeSchuytner - SVP...
2023-11-07 07:29:41 ET More on Mersana Therapeutics Mersana Therapeutics: Still In 'Show Me' Territory Mersana stock jumps 7% as FDA lifts clinical hold on cancer drug Mersana Therapeutics appoints Martin Huber as CEO Seeking Alpha’s Quant Rating on Me...
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current o...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Mersana Therapeutics Inc. (MRSN) is expected to report $-0.31 for Q3 2023
2023-11-06 13:09:53 ET Mersana Therapeutics ( NASDAQ: MRSN ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is -$0.34 and the consensus Revenue Estimate is $8.68M (+55.8% Y/Y). Over the last 1 year,...
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday. Shares of Hormel Foods Corporation (NYSE: HRL) rose sharp...